Psoriasis Treatment Finishes PoC Clinical Trial Testing

Category Archives: March 2016

Psoriasis Treatment Finishes PoC Clinical Trial Testing

Psoriasis Treatment Finishes PoC Clinical Trial Testing

Psoriasis Drug Will Undergo Further Research Trials To Test Effectiveness After completing a proof-of-concept (PoC) clinical trial, Vitae Pharmaceutical’s psoriasis drug proved to show its efficacy worth through the reduction of psoriasis severity. As a result, it will be designated the opportunity to undergo further clinical research trials. About The Psoriasis Drug The drug itself is referred to as VTP-43742. Unlike most psoriasis drugs in the market, VTP-43742 finds itself as an oral therapy in an otherwise injectable treatment-market, with Novartis’ Cosentyx leading the pack....More

Positive Clinical Trial Results Allow FDA To Approve New HIV Treatment

Positive Clinical Trial Results Allow FDA To Approve New HIV Treatment

Single Pill Combination Drug to Treat HIV Type-1 Gilead Sciences announced early this March that the U.S. Food and Drug Administration has approved Odefsey for treating HIV-1 infections. Odefsey, a single tablet, is a combination drug made up of emtricitabine, rilpivirine, and tenofovir aladfenamide (TAF). It has been approved to treat HIV type-1, the most common form of HIV. In November of last year, Genvoya, another Gilead drug treating HIV, was the first drug containing TAF to receive FDA approval. Odefsey, now the second FDA-approved TAF drug, is now the smallest single tablet r...More

Follicular Lymphoma Drug Approved by the FDA

Follicular Lymphoma Drug Approved by the FDA

Trial Results Show Significant Results Thereby Obtaining FDA Approval Genentech announced the FDA approval for their anti-CD20 agent drug, Gazyva (obinutuzumab), for follicular lymphoma patients who relapsed after, or are refractory to, a rituximab-containing regimen. This FDA approval was given after significant results were shown during the phase III clinical research trial for their Gazyva drug. Sandra Horning, MD, Genentech’s CMO and head of Global Product Development stated, “people with follicular lymphoma whose disease returns or worsens despite treatment with a Rituxa...More

Positive Results from AML Clinical Research Trial – Midostaurin

Positive Results from AML Clinical Research Trial – Midostaurin

Trial Results Pave Way for Breakthrough Therapy Drug Designation Status Following the Phase III RATIFY clinical trial, Novartis received the Breakthrough Therapy drug designation for the acute myeloid leukemia drug, midostaurin. The Breakthrough Therapy drug designation allows for the expedition of drug development and review for medicines that treat serious or life-threatening conditions. The drug must have demonstrated quantitative improvement over a current available therapy on at least one clinically determined endpoint. In this case, the compound PKC412 (midostaurin) was compare...More